Stage IV Prostate Cancer AJCC v7 Clinical Trial
Official title:
A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-Prostatectomy
Verified date | December 2021 |
Source | University of Washington |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II trial studies how well apalutamide, abiraterone acetate, prednisone, degarelix, and indomethacin work in treating patients with prostate cancer that has spread from where it started to nearby tissue or lymph nodes before surgery. Androgen can cause the growth of tumor cells. Hormone therapy using apalutamide, abiraterone acetate, prednisone, degarelix, and indomethacin may fight prostate cancer by lowering the amount of androgen the body makes and/or blocking the use of androgen by the tumor cells.
Status | Completed |
Enrollment | 22 |
Est. completion date | December 10, 2020 |
Est. primary completion date | December 10, 2018 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Willing and able to provide written informed consent - Eastern Cooperative Oncology Group (ECOG) performance status =< 2 - Documented histologically confirmed adenocarcinoma of the prostate - Willing to undergo prostatectomy as primary treatment for localized prostate cancer - High risk prostate cancer (per National Comprehensive Cancer Network [NCCN] criteria): Gleason score 8-10 or T3a or PSA > 20 ng/mL or very-high risk prostate cancer (per NCCN criteria): T3b-T4 - Serum testosterone >= 150 ng/dL - Able to swallow the study drugs whole - Willing to take abiraterone acetate on an empty stomach (no food should be consumed at least two hours before and for one hour after dosing) - Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug; must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug - Medications known to lower the seizure threshold (see list under prohibited meds) must be discontinued or substituted at least 4 weeks prior to study entry Exclusion Criteria: - Prior local therapy to treat prostate cancer (e.g. radical prostatectomy, radiation therapy, brachytherapy) - Prior use of apalutamide, abiraterone acetate or degarelix - Prior or ongoing systemic therapy for prostate cancer including, but not limited to: - Hormonal therapy (for example [e.g.] leuprolide, goserelin, triptorelin, degarelix) - Cytochrome P450 (CYP)-17 inhibitors (e.g. ketoconazole) - Antiandrogens (e.g. bicalutamide, nilutamide) - Second generation antiandrogens (e.g. enzalutamide, apalutamide) - Immunotherapy (e.g. sipuleucel-T, ipilimumab) - Chemotherapy (e.g. docetaxel, cabazitaxel) - Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of informed consent to participate in this study - Any psychological, familial, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule - Absolute neutrophil count [ANC] < 1500/mm^3 - Platelet count < 100,000/mm^3 - Hemoglobin < 9 g/dL - Total bilirubin > 1.5 x upper limit of normal (ULN) - Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >= 2.5 x ULN; Note: in subjects with Gilbert's syndrome, if total bilirubin is > 1.5 x ULN, measure direct and indirect bilirubin and if direct bilirubin is =< 1.5 x ULN, subject may be eligible - Abnormal kidney function (glomerular filtration rate GFR < 45 mL/min) - Serum albumin < 3 g/dL - Serum potassium < 3.5 mmol/L - Seizure or known condition that may pre-dispose to seizure (e.g. prior stroke within 1 year to randomization, brain arteriovenous malformation, schwannoma, meningioma, or other benign central nervous system [CNS] or meningeal disease which may require treatment with surgery or radiation therapy) - Severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (eg, pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to randomization - History of stroke within the last 5-years - History of gastrointestinal (GI) bleed requiring transfusion - History of peptic ulcer disease requiring treatment within the last 5-years - History of asthma that is nonsteroidal anti-inflammatory drug (NSAID)-induced or with asthma that is classified as 'mild-persistent' or worse (based on symptoms occurring more than 2 days per week) - Uncontrolled hypertension - Gastrointestinal disorder affecting absorption - Active infection (eg, human immunodeficiency virus [HIV] or viral hepatitis) - Any chronic medical condition requiring a higher dose of corticosteroid than 10 mg prednisone/ prednisolone once daily - Any condition that in the opinion of the investigator, would preclude participation in this study - Child Pugh class B & C - Pre-existing viral hepatitis |
Country | Name | City | State |
---|---|---|---|
United States | Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
University of Washington | Janssen Scientific Affairs, LLC, National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pathologic Complete Response Rate as Assessed From Prostatectomy Specimens Following Neoadjuvant Treatment | Pathologic complete response is defined as no evidence of cancer on fully submitted prostatectomy specimens using standard surgical pathology assessments (i.e. H&E assessment will be used for the purpose of defining pathologic complete response per protocol) at 3 months. | At 3 months | |
Secondary | Apoptotic Index (i.e. Percentage of Tumor Cells Undergoing Apoptosis) | Will be determined by cleaved caspase-3 immunohistochemistry. | At 3 months | |
Secondary | Number of Patients With a Negative Margin After 3 Months of Treatment | The absence of tumor cells at the prostate margin will be assessed using standard pathological practices on prostatectomy specimens (i.e. after 3 months of treatment). | At 3 months | |
Secondary | Overall Survival (OS) | Will will report the number of participants alive at 2-years following enrollment. | At 2 years | |
Secondary | Number of Patients With a Near Pathologic Complete Response After 3 Months of Treatment | The near pathologic complete response will be defined as =< 5 mm of residual tumor as assessed on prostatectomy specimens after 3 months of treatment. | At 3 months | |
Secondary | Number of Patients With no Nodal Metastases After 3 Months of Treatment. | The presence of tumor cells within surgically excised lymph nodes will be assessed after 3 months of treament. | At 3 months | |
Secondary | Number of Patients With Pathologic T3 Disease After 3 Months of Treatment. | The presence of T3 disease (e.g. extraprostatic tumor not invading adjacent structures) will be determine from the prostatectomy specimen after 3 months of treament. | At 3 months | |
Secondary | Number of Participants Without Biochemical Failure at 2 Years | Prostate-specific antigen progression (i.e. biochemical failure) will be defined per the American Urological Association guidelines (i.e. confirmed prostate-specific antigen post-radical prostatectomy >= 0.2 ng/mL). We will report the number of patients without biochemical failure at 2 years. | At 2 years | |
Secondary | The Proportion of Men Who Receive Adjuvant Radiation Therapy | Patients that received radiation following prostatetomy | Up to 1 year post prostatectomy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02522715 -
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01480154 -
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
|
Phase 1 | |
Completed |
NCT00064129 -
Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer
|
Phase 1 | |
Completed |
NCT01576172 -
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01638533 -
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
|
Phase 1 | |
Completed |
NCT00942331 -
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
|
Phase 3 | |
Terminated |
NCT02565901 -
Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03421782 -
Fatigue Interventions in Cancer (Exercise Intervention)
|
Phase 2 | |
Completed |
NCT03448458 -
Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Completed |
NCT03368547 -
68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery
|
N/A | |
Completed |
NCT02555189 -
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression
|
Phase 1/Phase 2 | |
Recruiting |
NCT01050504 -
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
|
||
Recruiting |
NCT05334069 -
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
|
||
Recruiting |
NCT04775355 -
Study to Detect Changes in Urinary and Gut Microbiome During Androgen Deprivation Therapy and Radiation Therapy in Patients With Prostate Cancer
|